These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12956548)

  • 1. Administration of IV medications via soluset.
    Ford NA; Drott HR; Cieplinski-Robertson JA
    Pediatr Nurs; 2003; 29(4):283-6, 319. PubMed ID: 12956548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent.
    Mogayzel PJ; Pierce E; Mills J; McNeil A; Loehr K; Joplin R; McMahan S; Carson KA
    Pediatr Nurs; 2008; 34(6):464-8; quiz 468-9. PubMed ID: 19263753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of tobramycin delivery by four i.v. infusion methods.
    Pleasants RA; Sawyer WT; Williams DM; McKenna WR; Brown JM; Powell JR
    Clin Pharm; 1988 May; 7(5):367-73. PubMed ID: 3383542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The decision to use topical anesthetic for intravenous insertion in the pediatric emergency department.
    Fein JA; Gorelick MH
    Acad Emerg Med; 2006 Mar; 13(3):264-8. PubMed ID: 16495423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An innovative method of administering i.v. medications to children.
    Axton SE; Hall B
    Pediatr Nurs; 1994; 20(4):341-4, 355. PubMed ID: 7885743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs.
    Asheim P; Spigset O; Aasarød K; Walstad RA; Uggen PE; Zahlsen K; Aadahl P
    Acta Anaesthesiol Scand; 2008 Feb; 52(2):243-8. PubMed ID: 18005375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Errors in preparation and administration of intravenous medications in the intensive care unit of a teaching hospital: an observational study.
    Fahimi F; Ariapanah P; Faizi M; Shafaghi B; Namdar R; Ardakani MT
    Aust Crit Care; 2008 May; 21(2):110-6. PubMed ID: 18387813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardizing IV infusion medication concentrations to reduce variability in medication errors.
    Bullock J; Jordan D; Gawlinski A; Henneman EA
    Crit Care Nurs Clin North Am; 2006 Dec; 18(4):515-21. PubMed ID: 17118306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
    Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
    Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tobramycin in ducks and sex-related differences.
    Dimitrova D; Moutafchieva R; Kanelov I; Dinev T; Lashev L
    Vet J; 2009 Mar; 179(3):462-4. PubMed ID: 18006340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic variability of extended interval tobramycin in burn patients.
    Bracco D; Landry C; Dubois MJ; Eggimann P
    Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous fluid therapy: a randomized controlled trial to investigate the effectiveness of the IV(2) flow medical device.
    Fraser N; Snyman JR; Wessels F; Nel G
    J Clin Nurs; 2007 Sep; 16(9):1593-601. PubMed ID: 17727580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.